Dow Pharma & Food Solutions, a division of The Dow Chemical Company (DOW), together with Colorcon Inc., will exhibit their next-generation METHOCEL DC2 polymer at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Expo in San Antonio, Tex., from Nov 10 to 14.
METHOCEL DC2 will help reduce development time and lower manufacturing costs. Direct compression can lessen waste, shorten development time and decrease manufacturing costs by up to 60%.
METHOCEL DC2 polymers are customized for improved flow and compressibility and facilitate greater uniformity in direct compression applications. These polymers are also expected to show processing improvements in roller compaction applications. There are three direct compression grades of METHOCEL DC2 available – K100 LV, K4M and K100M.
METHOCEL DC2 will be marketed under the Dow-Colorcon Controlled Release Alliance. Colorcon and Dow Pharma & Food Solutions formed a global Controlled Release Alliance in 2007 to accelerate pharmaceutical product development efforts and penetrate markets globally.
Dow released its third-quarter results in Oct 2013. The company posted a profit of $594 million or 49 cents a share, a 20% rise from $497 million or 42 cents a share registered a year ago. Barring costs associated with its restructuring program, Dow earned 50 cents a share in the quarter. It, however, missed the Zacks Consensus Estimate by 4 cents.
Revenues edged up roughly 1% year over year to $13,734 million in the reported quarter, as gains from agricultural sciences, coatings, performance plastics and electronics were offset by decline in performance materials and feedstocks and energy. Sales in emerging markets rose 5%. However, revenues missed the Zacks Consensus Estimate of $13,946 million.
Dow currently carries a Zacks Rank #3 (Hold).
Other companies in the chemical industry worth considering include Methanex (MEOH), Asahi Kasei (AHKSY) and DuPont (DD). While both Methanex and Asahi Kasei hold a Zacks Rank #1 (Strong Buy), DuPont retains a Zacks Rank #2 (Buy).
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment